Spero Therapeutics
Update in progressSPRO (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Spero Therapeutics, Inc. is a clinical‑stage biopharmaceutical company focused on developing new treatments for multi‑drug resistant bacterial infections and rare diseases in the United States. Its lead program, Tebipenem HBr (tebipenem pivoxil hydrobromide), is an oral carbapenem for complicated UTIs and pyelonephritis in adults, with Phase 3 progress. The company licenses tebipenem pivoxil and Tebipenem HBr to Meiji Seika Pharma and SPR206 to Everest Medicines for Greater China, Korea, and SE Asia. Founded 2013, based in Cambridge, MA.
Company score
- Sentiment
- -0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.30
- Governance
- -0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!